The use of SGLT2 to improve clinical outcome in patients with heart failure and chronic kidney disease: a systematic review
Article Sidebar
Main Article Content
Abstract
Objective: To identify the benefits of using sodium-glucose cotransporter inhibitor (iSGLT2) in patients with or without diabetes mellitus 2 and chronic kidney disease. Methods: This is a systematic intervention review conducted from detailed studies found in the following databases: U.S. National Library of Medicine and the National Institute of Health, Wiley Online Library and Excerpta Medica dataBASE (Embase). The Health Sciences Descriptors were used: ''Sodium-Glucose Transporter 2 Inhibitors'' AND ''Heart Failure''. The total sample of articles went through inclusion and exclusion criteria, resulting in 14 articles. Only randomized clinical trials that contemplated the research question, which were relevant and current to the theme, were used. Results: We verified that this class of iSGLT2 drugs reduces cardiovascular death and hospitalization in patients with reduced or preserved left ventricular ejection fraction. These medications have shown promise in advanced chronic kidney disease. Final considerations: Using a group of drugs discovered and tested less than a decade ago, further studies are needed to ensure greater safety and use of drugs in stage 5 chronic kidney disease, enabling to prevent adverse reactions and ensure longevity.
Article Details
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
References
2. BHATT DL, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. New England Journal of Medicine, 2021; 384(2): 117-128.
3. BHATT DL, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. New England Journal of Medicine, 2021; 384(2): 129-139.
4. BOORSMA EM, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. European journal of heart failure, 2021; 23(1): 68-78.
5. CANNON CP, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New England Journal of Medicine, 2020; 383(15): 1425-1435.
6. CARDOSO J, et al. SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction. Revista Portuguesa de Cardiologia (English Edition), 2021; 40(9): 687-693.
7. COWIE MR e FISHER, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology, 2020; 17(12): 761-772.
8. EMPA-KIDNEY C. Empagliflozin in patients with chronic kidney disease. New Engl Jou of Medic, 2022.
9. GALVÃO TF e PEREIRA, MG, Avaliação da qualidade da evidência de revisões sistemáticas. Epidemiologia e Serviços de Saúde, 2015; 24: 173-175.
10. HALLIDAY BP, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. The Lancet, 2019; 393(10166): 61-73.
11. HEERSPINK HJL, et al. Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 2020; 383(15): 1436-1446.
12. HEIDENREICH PA, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 2022; 79(17): e263-e421.
13. LEE MMY, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 2021; 143(6): 516-525.
14. MCMURRAY JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 2019; 381(21): 1995-2008.
15. MOHER D, et al. Preferred reporting items forsystematic reviews and meta-analyses: the PRISMAstatement. Int J Surg, 2009; 8(5): 336-341.
16. PACKER M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 2020; 383(15): 1413-1424.
17. PAGE MJ, et al. A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas. Epidemiologia e Serviços de Saúde, 2022; 31: 2.
18. PEREIRA GAR, et al. Iron Deficiency in Heart Failure with Reduced Ejection Fraction: Pathophysiology, Diagnosis and Treatment. Arquivos brasileiros de cardiologia, 2022; 118: 646-654.
19. PERKOVIC V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 2019; 380(24): 2295-2306.
20. SAMPAIO RF e MANCINI MC. Estudos de revisão sistemática: um guia para síntese criteriosa da evidência científica. Brazilian Journal of Physical Therapy, 2007; 11: 83-89.
21. SANTOS CMC, et al. The PICO strategy for the research question construction and evidence search. Revista latino-americana de enfermagem, 2007; 15: 508-511.
22. SHEA BJ, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC medical research methodology, 2007; 7(1): 1-7.
23. SOLOMON SD, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, 2022; 387(12): 1089-1098.
24. VOORS AA, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature medicine, 2022; 28(3): 568–574.
25. WIVIOTT SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 2019; 380(4): 347-357.
26. ZINMAN B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 2015; 373(22): 2117-2128.